Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
FLOVENT DISKUS 100 is a dry powder inhaler formulation of fluticasone propionate, an inhaled corticosteroid used primarily for asthma maintenance and control. It delivers 100 mcg of active drug per inhalation and is indicated for chronic asthma management in adults and children. The mechanism involves local anti-inflammatory activity in the airways, reducing airway hyperresponsiveness and symptoms.
With LOE approaching, the brand is in mature stage with likely defensive positioning and team focus shifting toward lifecycle extension or transition management.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
Worked on FLOVENT DISKUS 100 at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on FLOVENT DISKUS in its LOE-approaching stage offers exposure to mature-market dynamics, pricing pressures, and lifecycle management rather than launch excitement. Professionals will develop expertise in competitive intelligence, generic defense strategies, and value-based reimbursement—skills increasingly relevant as more blockbusters reach patent expiry.